A Collaborative Effort to Overcome Data Fragmentation

During the COVID-19 pandemic, a vast amount of clinical data was generated worldwide. However, due to varying recording formats across institutions, integrating and analyzing this data posed significant challenges. To address this data fragmentation, the U.S. Food and Drug Administration (FDA), the Reagan-Udall Foundation for the FDA, and Friends of Cancer Research, an organization dedicated to advancing cancer research, joined forces to launch a Real-World Data (RWD) standardization project for COVID-19. They established the 'COVID-19 Evidence Accelerator,' involving over 200 public and private organizations, to harmonize disparate data and transform it into usable Real-World Evidence (RWE).

Achieving Interoperability Through Common Data Model (CDM) Mapping

The key achievement of this project was the standardization of diverse data models used by various healthcare institutions into a unified structure for data exchange. Researchers successfully mapped key data elements, such as demographic characteristics, diagnostic test results, medications, and clinical outcomes of COVID-19 patients, to major Common Data Models (CDMs), including OMOP, PCORnet, Sentinel, and i2b2/ACT. This enabled the creation of a 'federated distributed analysis infrastructure' that allows the same analytical queries to be sent to each database network without physically moving sensitive patient data, enabling rapid aggregation of statistical results.

Facilitating the Validation of Real-World Effectiveness of Key Treatments

The harmonization and standardization of RWD elements have significantly contributed to validating the safety and efficacy of treatments such as Remdesivir (brand name: Veklury) from Gilead Sciences (GILD) and Hydroxychloroquine, which initially faced controversy. Before large-scale, randomized controlled trials (RCTs) yielded results, parallel analyses were conducted using the standardized distributed research infrastructure, allowing for near real-time comparison of data from clinical practice. This played a crucial role in helping regulatory authorities and healthcare professionals demonstrate the actual efficacy of the treatments and maintain post-Emergency Use Authorization (EUA) safety surveillance.

Reducing Post-Market Surveillance Costs and Transforming Regulatory Science

The establishment of a standardized RWD platform presents an opportunity to revolutionize the cost structure of post-market surveillance (PMS) and expansion of indications for new drugs, which global pharmaceutical companies such as Pfizer (PFE) and Merck & Co. (MRK) must conduct after drug development. The market value of specialized healthcare RWD analysis companies, such as Aetion and Syapse, is increasing, and pharmaceutical companies can significantly reduce the data preparation costs associated with preparing clinical evidence for submission to regulatory agencies. Ultimately, this is expected to shorten the timeline from data collection to decision-making, significantly enhancing the ability to respond to future public health crises.